CO2021004004A2 - Composición tópica inyectable - Google Patents
Composición tópica inyectableInfo
- Publication number
- CO2021004004A2 CO2021004004A2 CONC2021/0004004A CO2021004004A CO2021004004A2 CO 2021004004 A2 CO2021004004 A2 CO 2021004004A2 CO 2021004004 A CO2021004004 A CO 2021004004A CO 2021004004 A2 CO2021004004 A2 CO 2021004004A2
- Authority
- CO
- Colombia
- Prior art keywords
- injection
- topical composition
- dca
- dry powder
- present
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
RESUMEN La presente invención hace referencia a una formulación de polvo seco para inyección de un ingrediente DCA. La presente invención es una formulación de polvo seco que tiene una excelente estabilidad de almacenamiento, un pH de 8,2 o menos, de modo que, cal disolverse en agua para inyección, el dolor se reduce durante la inyección al formar un entorno de pH más cercano al del cuerpo humano que el las inyecciones convencionales y permite que el DCA se disuelva bien en el agua de inyección sin precipitarse.GG
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190015232A KR102064864B1 (ko) | 2019-02-08 | 2019-02-08 | 국소 주사용 조성물 |
PCT/KR2020/001686 WO2020162685A1 (ko) | 2019-02-08 | 2020-02-06 | 국소 주사용 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2021004004A2 true CO2021004004A2 (es) | 2021-05-31 |
Family
ID=69158535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2021/0004004A CO2021004004A2 (es) | 2019-02-08 | 2021-03-30 | Composición tópica inyectable |
Country Status (8)
Country | Link |
---|---|
US (1) | US20210220260A1 (es) |
EP (1) | EP3871661A4 (es) |
JP (1) | JP7224687B2 (es) |
KR (1) | KR102064864B1 (es) |
CN (1) | CN112955125B (es) |
BR (1) | BR112021008420A2 (es) |
CO (1) | CO2021004004A2 (es) |
WO (1) | WO2020162685A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102064864B1 (ko) * | 2019-02-08 | 2020-01-10 | (주)제테마 | 국소 주사용 조성물 |
KR102598758B1 (ko) * | 2020-02-26 | 2023-11-07 | 주식회사 엘지화학 | 데옥시콜릭산을 포함하는 약제학적 조성물 |
CN116617160A (zh) * | 2023-07-25 | 2023-08-22 | 山东则正医药技术有限公司 | 水性混悬液及制备方法、冻干粉及应用、脂肪消减注射剂 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20010045518A (ko) * | 1999-11-05 | 2001-06-05 | 이규현 | 프로포폴의 안정화된 주사제용 약제학적 조성물 및 그의제조방법 |
EP2422789B1 (en) | 2004-05-19 | 2017-11-22 | Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center | Injectable coposition comprising sodium deoxycholate |
JP2013518097A (ja) * | 2010-01-26 | 2013-05-20 | イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム エルティーディー | 肺高血圧を予防および治療するための組成物および方法 |
KR101919269B1 (ko) | 2011-08-23 | 2018-11-15 | 키쎄라 바이오파마슈티컬즈 인코포레이티드 | 데옥시콜린산 및 그의 염들의 제형물들 |
KR101932247B1 (ko) * | 2012-05-17 | 2018-12-21 | (주)아모레퍼시픽 | 데옥시콜린산 또는 그의 염을 포함하는 조성물 및 효소의 안정화 방법 |
KR102107831B1 (ko) * | 2014-06-27 | 2020-05-07 | (주)메디톡스 | 지방 감소를 위한 담즙산 및 염의 방법 및 조성물 |
JP2018532806A (ja) * | 2015-11-04 | 2018-11-08 | キセラ バイオファーマシューティカルズ インコーポレイテッド | デオキシコール酸およびその塩による蓄積脂肪の処置方法 |
US20180078621A1 (en) * | 2016-09-22 | 2018-03-22 | Kyoung Lack Lee | Composition for hypotonic lipolysis and manufacturing method thereof |
KR102093872B1 (ko) * | 2017-07-03 | 2020-03-27 | 진호성 | 지방제거용 주사제 조성물 및 이의 제조방법 |
KR101865562B1 (ko) * | 2017-11-03 | 2018-06-08 | 주식회사 펜믹스 | 포스포콜린 유도체를 포함하는 지방분해 조성물 |
KR102064864B1 (ko) * | 2019-02-08 | 2020-01-10 | (주)제테마 | 국소 주사용 조성물 |
-
2019
- 2019-02-08 KR KR1020190015232A patent/KR102064864B1/ko active IP Right Grant
-
2020
- 2020-02-06 BR BR112021008420-7A patent/BR112021008420A2/pt unknown
- 2020-02-06 CN CN202080005682.9A patent/CN112955125B/zh active Active
- 2020-02-06 WO PCT/KR2020/001686 patent/WO2020162685A1/ko unknown
- 2020-02-06 EP EP20753264.9A patent/EP3871661A4/en active Pending
- 2020-02-06 JP JP2021524005A patent/JP7224687B2/ja active Active
-
2021
- 2021-03-30 CO CONC2021/0004004A patent/CO2021004004A2/es unknown
- 2021-04-08 US US17/225,309 patent/US20210220260A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20210220260A1 (en) | 2021-07-22 |
WO2020162685A1 (ko) | 2020-08-13 |
CN112955125B (zh) | 2024-05-28 |
EP3871661A4 (en) | 2022-07-13 |
EP3871661A1 (en) | 2021-09-01 |
BR112021008420A2 (pt) | 2021-09-14 |
CN112955125A (zh) | 2021-06-11 |
JP7224687B2 (ja) | 2023-02-20 |
JP2022506578A (ja) | 2022-01-17 |
KR102064864B1 (ko) | 2020-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021004004A2 (es) | Composición tópica inyectable | |
UY39027A (es) | Uso de favipiravir en el tratamiento de la infección por coronavirus | |
CR20170242A (es) | Benzamidas sustituidas copn 1,3-tiazol-2-ilo | |
HRP20240485T1 (hr) | Pripravci glp-1 i njihova upotreba | |
CL2023000289A1 (es) | Combinaciones para el tratamiento de cáncer | |
CO2020001244A2 (es) | Derivados de quinolina para tratar infecciones con helmintos | |
NI200800169A (es) | Uso de derivados de sulfamidas heterocíclicas benzo-fusionadas para el tratamiento del dolor | |
BR112014025564B8 (pt) | composto heterocíclico contendo nitrogênio ou sal do mesmo, composição farmacêutica e uso da mesma | |
BR112022010112A2 (pt) | Aminoquinolonas substituídas como inibidores de dgkalfa para ativação imunológica | |
MX2020008173A (es) | Combinacion de un agente antimuscarinico o de uno anticolinergico y acido lipoico, y sus usos. | |
CL2016000950A1 (es) | Composición farmacéutica acuosa que comprende insulina glulisina y metionina; kit farmacéutico; uso en el tratamiento de la diabetes tipo 1 ó 2. | |
BR112015026247A8 (pt) | composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit | |
CO2023008949A2 (es) | Forma cristalina de tolebrutinib, método de preparación y uso de la misma | |
DE602004015725D1 (de) | Stabilisierte lyophilisierte zubereitungen mit gewebefaktor-inhibitor (tfpi) oder varianten des gewebefaktor-inhibitors | |
CO2020013876A2 (es) | Nuevos derivados de quinolina | |
CL2022002566A1 (es) | Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572) | |
BR112018069712A2 (pt) | composto ou um sal farmacologicamente aceitável do mesmo, composição farmacêutica, método para administração de uma quantidade eficaz de uma composição farmacêutica, e, inibidor de tnf-a. | |
CL2020002544A1 (es) | Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret | |
BR112022001567A2 (pt) | Derivados de isoquinolina e seu uso para o tratamento de infecções parasitárias. | |
CO2019006652A2 (es) | Amidas aromáticas de ácidos carboxílicos como antagonistas del receptor de bradiquinina b1 | |
CO2021011023A2 (es) | Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos | |
BR112022000914A2 (pt) | Composição farmacêutica | |
ECSP23077322A (es) | Derivados de fósforo como nuevos inhibidores de sos1 | |
BR122021012549B8 (pt) | Composição de dissolução oral de melatonina com agente acidificante que torna melatonina solúvel em saliva | |
BR112022020315A2 (pt) | Novos compostos anti-helmínticos |